SCHEMBL266599

SCHEMBL266599

Cc1coc2c1C(=O)CCC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NQO1 P15559 2/20 0.36
POR P16435 2/20 0.36
BRD4 O60885 6/20 0.36
TSHR P16473 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP2A6 P11509 2/20 0.34
CYP2A13 Q16696 1/20 0.34
MAPK1 P28482 2/20 0.34
MAPT P10636 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HPGD P15428 2/20 0.34
MAOA P21397 1/20 0.33
MEN1 O00255 1/20 0.33
CES2 O00748 1/20 0.33
APAF1 O14727 1/20 0.33
TERT O14746 1/20 0.33
EED O75530 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19568230 0.77 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2NQO1PORBRD4
SCHEMBL13990465 0.76 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2
SCHEMBL20992387 0.76 SMN1; SMN2 (0.39) ALDH1A1SMN1; SMN2BRD4
SCHEMBL9803021 0.73 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2BRD4TSHRKDM4E
SCHEMBL2314210 0.72 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2HPGD
SCHEMBL13021597 0.72
SCHEMBL4899883 0.71 BRD4 (0.47) ALDH1A1SMN1; SMN2BRD4TSHRKDM4E
SCHEMBL5236831 0.71 L3MBTL1 (0.42) ALDH1A1SMN1; SMN2TSHRKDM4EHSD17B10
SCHEMBL5189062 0.71 NAMPT (0.41) ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5444456 0.71 NAMPT (0.41) ALDH1A1SMN1; SMN2HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016097496-A1 USE OF EVODONE DERIVATIVES AS REPELLENT, NOVEL EVODONE DERIVATIVES AND SYNTHESIS PROCESS CHARABOT (FR) 2016-06-23 WO claimed
EP-3452456-B1 BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2023-07-05 EP disclosed
CN-110804035-B Tetrahydrobenzofuran Mannich alkali compounds, and preparation method and application thereof 三峡大学 2022-11-18 CN disclosed
CN-110804035-A Tetrahydrobenzofuran Mannich alkali compounds, and preparation method and application thereof 三峡大学 2020-02-18 CN disclosed
CN-106749135-B Substituted benzofuran formyl hydrazone analog derivative and preparation method thereof 浙江大学 2019-07-19 CN disclosed
CN-106905340-B Benzofuran fluoro flavanone derivative and preparation method thereof 浙江大学 2019-02-01 CN disclosed
CN-106279082-B Substituted furans chalcone derivative and preparation method thereof 浙江大学 2019-02-01 CN disclosed
CN-106279083-B A kind of furocoumarin analog derivative and preparation method thereof 浙江大学 2019-01-08 CN disclosed
WO-2017193063-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES (US) 2017-11-09 WO disclosed
CN-106336416-A Furan flavone derivative and preparation method thereof 浙江大学 2017-01-18 CN disclosed
US-20080312435-A1 Imine Compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-18 US disclosed
US-20080312435-A1 Imine Compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-18 US disclosed
EP-1995240-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-26 EP disclosed
EP-1741428-A2 Cell adhesion inhibitors Biogen Idec MA, Inc. (US) 2007-01-10 EP disclosed
US-20040142976-A1 Pyridylfuran and pyridylthiophene compounds PFIZER INC. 2004-07-22 US disclosed
US-6696470-B2 FOR THERAPY OF ARTHRITIS, ASTHMA, BONE RESORPTION DISEASE, CACHEXIA, CARDIOVASCULAR DISEASE, CEREBRAL MALARIA, CROHN'S DISEASE, DIABETES, FEVER OR MYALGIA DUE TO INFECTION, GOUT, GRAFT VERSUS HOST REACTION, INFLAMMATION OF ORGANS, ETC. PFIZER INC. 2004-02-24 US disclosed
US-20020022729-A1 Pyridylfuran and pyridylthiophene compounds KAWAI AKIYOSHI (JP) 2002-02-21 US disclosed
EP-0853083-B1 Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof PFIZER (US) 2001-09-12 EP disclosed
US-6048880-A THERAPY FOR CYTOKINE SENSITIVE DISEASES PFIZER PHARAMACEUTICALS INC. (JP) 2000-04-11 US disclosed
EP-0853083-A1 Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof PFIZER INC. (US) 1998-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312435-A1 Imine Compound CNR1, CNR2, HRH4 ALDH1A1 2674/4885SMN1; SMN2 1844/4885NQO1 1815/4885
US-20040142976-A1 Pyridylfuran and pyridylthiophene compounds MC2R, FCGR2A, OGFR ALDH1A1 789/4885SMN1; SMN2 3438/4885NQO1 893/4885
US-20020022729-A1 Pyridylfuran and pyridylthiophene compounds MC2R, CRHR1, NR3C2 ALDH1A1 729/4885SMN1; SMN2 3340/4885NQO1 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.